← Back to Search

Open physician access to Venus 1000 CVP data for Sepsis

N/A
Waitlist Available
Led By Mark Favot, MD
Research Sponsored by Mespere Lifesciences Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

Study Summary

The purpose of this study is to evaluate the impact that the Venus 1000 non-invasive CVP system has on the management of emergency department (ED) patients with fluid sensitive conditions.

Eligible Conditions
  • Sepsis
  • Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
30-day Readmission
Secondary outcome measures
Dose, timing and duration of all IV vasoactive medications
Duration of respiratory support
Length of stay in hospital
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Open physician access to Venus 1000 CVP dataExperimental Treatment1 Intervention
Group II: No open physician access to Venus 1000 CVP dataExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Mespere Lifesciences Inc.Lead Sponsor
10 Previous Clinical Trials
462 Total Patients Enrolled
1 Trials studying Sepsis
40 Patients Enrolled for Sepsis
Wayne State UniversityOTHER
307 Previous Clinical Trials
108,384 Total Patients Enrolled
2 Trials studying Sepsis
125 Patients Enrolled for Sepsis
Mark Favot, MDPrincipal InvestigatorWayne State University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
2014. "Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02258984.
All > Heart Failure With Preserved Ejection Fraction > Sepsis
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top